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Summary 
Background: The cell population data (CPD) measured by
Sysmex XN-9000 can be used for screening many hema-
tological and non-hematological disorders. Since little in -
formation is available on harmonization of CPD among dif-
ferent instrumentation and clinical laboratories, this study
aimed at assessing the current degree of CPD harmoniza-
tion between separate Sysmex XN modules allocated to
the same laboratory.
Methods: A total number of 78291 data were used for
verification of within-run imprecision, analyzers harmoni -
zation, reference ranges and assessment of blood sample
stability of CPD parameters, including results of daily qual-
ity control testing and those generated in samples collected
from blood donors and healthy volunteers. 
Results: Within-run imprecision of CPD parameters ranged
between 0.4 and 14.1%. Good agreement was found
among five different XN-modules, especially when values
were adjusted after calculation of instrument-specific align-
ment factors. The bias of all parameters remained always
Kratak sadr`aj
Uvod: Podaci o }elijskoj populaciji (cell population data,
CPD) me reni pomo}u ure|aja Sysmex XN-9000 mogu se
koristiti za skrining mnogih hematolo{kih i nehematolo{kih
pore me }aja. Po{to je dostupno malo informacija o uskla -
|ivanju CPD izme|u razli~itih instrumenata i klini~kih labora-
torija, ova stu dija imala je za cilj procenu trenutnog stepena
harmonizacije CPD izme|u razli~itih Sysmex XN modula
raspolo`ivih u istoj laboratoriji. 
Metode: Ukupno 78291 podataka upotrebljeno je za veri-
fikovanje nepreciznosti unutar serije, harmonizacije analiza-
tora, referentnih opsega i pocenu stabilnosti uzoraka krvi za
CPD parametre, uklju~uju}i rezultate svakodnevnog testira -
nja kontrole kvaliteta i one generisane u uzorcima sakuplje -
nim od davalaca krvi i zdravih dobrovoljaca. 
Rezultati: Nepreciznost unutar serije za CPD parametre kre-
tala se izme|u 0,4 i 14,1%. Prona|eno je dobro slaganje
izme|u pet razli~itih XN modula, naro~ito po{to su vrednosti
prilago|ene posle ra~unanja faktora poravnanja specifi~nih
za instrument. Odstupanje za sve parametre ostajalo je uvek
List of abbreviations: BALG, alignment bias based on intra-individual
biological variation; BAPS, analytical performance specification for
bias; CVAPS, analytical performance specification for imprecision;
CVI, within-subject biological variation; CI, confidence interval; CPD,
cell population data; FSC, forward scatter; HA, hematological analyz-
ers; HFLC, high fluorescence lymphocytes cell; IAF, instrumental
alignment factor; LY, lymphocytes; LY-WX, lymphocyte complexity and
width of dispersion of the events measured; LY-WY, lymphocyte fluo-
rescence intensity and the width of dispersion; LY-WZ, lymphocyte cell
size and the width of dispersion; LY-X, lymphocyte cell complexity;
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Introduction
The development of innovative technologies
and analytical principles in flow cytometry has been
accompanied by commercialization of a new genera-
tion of hematological analyzers (HA) capable of gen-
erating both quantitative (i.e., cell counts and cellular
indices) and qualitative (e.g., morphological flags,
scattergrams) information, which also have a high
degree of analytical efficiency for identifying many
cellular abnormalities (1–3). The cell population data
(CPD) measured by HA reflect some morphological
parameters of white blood cell (WBC) subpopulations,
and can be used for screening many hematological
and non-hematological disorders. The Sysmex XN-
9000 (Sysmex Kobe Japan) not only measures con-
ventional hematologic parameters, but can also gen-
erate innovative WBC parameters such as high
fluorescence lymphocytes cell (HFLC) and CPD. The
analytical techniques are essentially based on fluores-
cence flow cytometry for WBC differential count, and
on a combination of forward scatter (FSC), side scat-
ter (SSC) and fluorescence intensity (SFL) for detect-
ing different WBC populations, respectively. These
three measurements, together with their relative dis-
tribution width (W), can then be combined for obtain-
ing CPD of neutrophils (NE), lymphocytes (LY) and
monocytes (MO) populations. 
Recent studies showed that NE CPD parameters
(i.e., NE-SSC, NE-SFL) may be useful for diagnosing
myelodysplastic syndromes and sepsis, whilst NE-SFL
and MO-WX may play a role in differential diagnosis
of some acute leukemias (4–9). Some LY CPD
param eters (i.e., LY-X, LY-Y and LY-Z) may then pro-
vide valuable information for screening lymphoprolif-
erative diseases (10, 11). Nevertheless, little informa-
tion is available on the analytical quality specification
of CPD, and even less is known on the degree of har-
monization of these measures among different instru-
mentation and clinical laboratories. This last aspect is
especially important due to the worldwide reorganiza-
tion of laboratory diagnostics, which increasingly
encompasses the shipment of blood specimens from
one laboratory to another, thus potentially jeopar -
dizing sample quality (12). Therefore, the aim of this
study was to assess the current degree of CPD har-
monization between separate Sysmex XN modules
installed in the same laboratory. 
Materials and Methods
Description of the XN-module hematological  
analyzer 
The XN-9000 is the largest core model belong-
ing to the XN-Series, being composed by up to seven
separate analytical modules. A typical combination
entails three »green« analyzers allocated for CBC and
DIFF profiles, two »blue« analyzers allocated for App-
RET, App PLT-F and App WPC analysis, along with a
single slide preparation unit (Autoslider SP-10;
Sysmex Co., Kobe, Japan) integrated with a slide pro-
cessing system (DI60; Sysmex Co., Kobe, Japan). The
analysis of all samples included in this study was car-
ried out according to manufacturer's instructions. The
quality of data was validated by routine use of internal
quality controls, based on three different levels of pro-
prietary materials. 
lower than the reference change values in samples stored
for up to 8 hours, regardless of storage temperature.
Conclusions: The imprecision of CPD parameters was
acceptable, except for those reflecting the dispersion of cel-
lular clusters. Due to the lack of reference control materi-
als, we showed that the use of data generated on a large
number of normal routine samples (i.e., a Moving Average
population) may be a reliable approach for testing analyz-
ers harmonization. Nevertheless, availability of both cali-
bration and quality control materials for these parameters is
highly advisable in the future. We finally showed that whole
blood samples may be stable for up to 2–4 hours for most
CPD parameters.
Keywords: cell population data, quality control, within-
run imprecision, reference range, stability
ispod referentnih vrednosti promena u uzorcima skladi{ te -
nim do 8 sati, bez obzira na temperaturu skladi{tenja. 
Zaklju~ak: Nepreciznost CPD parametara bila je prihvatljiva,
osim za one koji su odra`avali rasipanje }elijskih skupova.
Usled nedostatka referentnih kontrolnih materijala, pokazali
smo da upotreba podataka generisanih iz velikog broja nor-
malnih rutinskih uzoraka (npr. Moving Average populacija)
mogu slu`iti kao pouzdan pristup za testiranje harmonizacije
analizatora. Uprkos tome, u budu}nosti bi mnogo pomogla
dostupnost kako kalibracije tako i materijala za kontrolu
kvaliteta za ove parametre. Najzad, pokazali smo da uzorci
pune krvi mogu biti stabilni i do 2–4 sata za ve}inu CPD
parametara. 
Klju~ne re~i: podaci o }elijskoj populaciji, kontrola kva li -
teta, nepreciznost unutar serije, referentni opseg, stabilnost
LY-Y, lymphocyte fluorescence intensity; LY-Z, lymphocyte cell size;
MA, moving average; MCV, mean corpuscular volume; MO, mono-
cytes; MO-X, monocyte cell complexity; MO-Y, monocyte fluores-
cence intensity; MO-Z, monocyte cell size; MO-WX, monocyte com-
plexity and width of dispersion of the events measured; MO-WY,
monocyte fluorescence intensity and the width of dispersion; MO-WZ,
monocyte cell size and the width of dispersion; NE: neutrophils; NE-
FSC, neutrophil cell size; NE-SFL, neutrophil fluorescence intensity;
NE-SSC, neutrophil cell complexity; NE-WX, neutrophil complexity
and width of dispersion of the events measured; NE-WY, neutrophils
fluorescence intensity and the width of dispersion; NE-WZ, neutrophil
cell size and the width of dispersion; NRBCs, nucleated red blood
cells; OMV, overall median; RBC, red blood cell; RCV, reference
change values; RDW-CV, red blood cell distribution width; RT, room
temperature; SFL, fluorescence intensity; SSC, side scatter; W, distri-
bution width; WBC, white blood cell; XN-module, Sysmex XN-9000.
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Within-run imprecision of cell population data
Five blood samples collected in K3EDTA tubes
(Becton Dickinson, NJ) from a single healthy volun-
teer (the inclusion criteria were based on negative
clinical history and normal serum concentrations of
glucose, creatinine, aminotransferases, ferritin and C
reactive protein) were preliminary mixed, and five
identical aliquots were then produced. Within-run
imprecision of CPD parameters was assessed by per-
forming 10 consecutive measures of the five aliquots,
as recommended by the Clinical and Laboratory
Standards Institute (CLSI) document EP05-A3 (13).
All aliquots were then analyzed in all the five separate
XN-modules with a specific protocol, as follows: in
the first round the samples were analyzed from mod-
ule 1 to 5, in the second round from module 2 to 1,
up to the fifth round, when samples were analyzed
from module 5 to 1. The cycle was repeated twice.
The evaluation of imprecision was carried out
by comparison with analytical performance specifica-
tions for imprecision (CVAPS) of CPD parameters, as
described elsewhere by Buoro et al. (14).
Verification of analyzers harmonization
Venous blood samples were drawn from 30
apparently healthy blood donors (30-HBD) in
K3EDTA tubes in three different days (i.e., 10 sam-
ples per day over one month; November 2015), and
then analyzed within 30 minutes from collection on
each of the five XN-modules. The inclusion criteria
for these reference subjects were also based on a
negative clinical history and normal serum concentra-
tions of glucose, creatinine, aminotransferases, fer-
ritin and C reactive protein.
The so-called Moving Average (MA) was
assessed using all normal routine samples analyzed in
the local laboratory over one month (i.e., November
2015). The inclusion criteria were as follows: absence
of morphological flags, WBC count 4.0–10.0×
109/L, hemoglobin 120–170 g/L, mean corpuscular
volume (MCV) 84–98 fL, platelet count 150–450×
109/L, red blood cell (RBC) distribution width (RDW-
CV) <14.0%, nucleated RBCs (NRBCs) <0.01×
109/L, NE count 2.00–5.60×109/L, LY count 1.50–
3.50×109/L, MO count 0.30–0.80×109/L, eosinophil
count 0.10–0.60×109/L and basophil count <0.20×
109/L. According to these criteria, we finally selected
6,702 out of a total number of 35,500 routine sam-
ples (18.9%) received in the laboratory during the 1-
month period. The daily results of normal level of the
control material e-CHECK (XN-Check; Sysmex,
Kobe, Japan) were also included in the evaluation.
XN-Check was repeated for 40 days, for a total of 40
measurements on each of the five XN-modules. The
median values of the CPD parameters obtained on
each of the five XN-modules of samples were then
compared. The overall harmonization of CPD param-
eters was finally assessed by calculating the percent-
age bias (Bias%) between the median value of results
of each XN-module and the median value of com-
bined results obtained with all the five XN-modules. 
Due to the lack of internal and external quality
controls for CPD parameters, we used the Overall
Median (OMV) of each parameter as the reference
value. The calculation of percentage difference
between CPD parameters on each XN-Module was
assessed using the formula [(median XN-Module –
OMV) / (Median XN-Module + OMV)/2)]*100, as
suggested by Fraser et al. (15). The percent differ-
ences (Bias%) were then compared to the analytical
performance specification for Bias % (BAPS%) report-
ed elsewhere (14), whilst alignment bias based on
intra-individual biological variation (BALG %) was cal-
culated according to Petersen et al. (16–18), using
the formula 0.33*CVI. The CVIs were obtained from
data earlier published by Buoro et al. (14). Difference
significance of Bias%, and between BAPS and BALG,
was assessed by estimating the overlap of 95% confi-
dence interval (CI).
The distribution of data was tested with Shapiro
and Wilk test (19). Results were compared with
Kruskal-Wallis test and one-way analysis of variance
(ANOVA).
Both MA, 30-HBD samples and XN-Check con-
trol blood assessment were repeated after two
months (January 2016). The possibility of introducing
an instrumental alignment factor (IAF) was tested, as
follows: overall mean/mean value of XN-module. 
Assessment of blood sample stability
Ten ostensibly healthy, adult, Caucasian volun-
teers (5 women and 5 men; mean age 37±1 years
and 35±2 years, respectively) were included in this
part of the study. The inclusion criteria were again
based on negative clinical history and normal serum
concentrations of glucose, creatinine, aminotrans-
ferases, ferritin and C reactive protein. Venous blood
samples (six samples for each subject) were drawn
from an antecubital vein into K3EDTA evacuated
blood tubes. The samples were analyzed 15–30 min
after the venipuncture (T0). Three tubes were stored
at Room Temperature (RT), whilst the remaining
three tubes drawn from each subject were aliquoted
and kept refrigerated at +4 °C. With the aim of study-
ing the effect of storage time, each sample was then
repeatedly measured after 4 hours (T4), 6 hours (T6),
8 hours (T8), 24 hours (T24), 36 hours (T36), up to
48 hours (T48) from collection, respectively. All
measurements were performed in duplicate. 
The differences between the various parameters
measured in the paired aliquots were then assessed
with Steel-Dwass-Critchlow-Fligner test (20–22), with
evaluation of Hodges-Lehmann location shift for mul-
tiple comparisons among different groups, after veri-
fication of values distribution with Shapiro-Wilk test.
P-values < 0.05 were considered statistically signifi-
cant. The results were finally reported as X (Tx-T0) in
absolute value. 
Percentage variations from the baseline result
(T0) in samples with statistically significant differ-
ences were then analyzed with Bland-Altman plots
(B%) and compared to BAPS% (14). The Bias% was
also compared with the respective reference change
values (RCV) (14).
Statistical analysis
The statistical analysis was performed using
Analyse-it™ software, version 3.90.5 (Analyse-it soft-
ware Ltd; Leeds, UK). The study was approved by
the ethical committee of the Papa Giovanni XXIII
Hospital and was carried out in accordance with the
Declaration of Helsinki under the terms of all relevant
local legislation.
Results
Within-run imprecision
The results of within-run imprecision (expressed
as coefficient of variation; CV) are shown in Table I.
The imprecision of NE-parameters was 0.4–5.5%,
whilst that of LY-parameters was 0.7–8.7%. Re mark -
able variability was noticed in the within-run impreci-
sion of MO-parameters across the five XN-modules,
being 0.8–14.1%. Acceptable performance com-
pared with the desirable analytical specification for
imprecision derived from biological variation data
published by Buoro et al. (14) was only met for NE-
SFL and LY-Y across the five XN-modules. Although
all CPD parameters reflecting cellular dispersion did
not even fulfill the minimum target of analytical
imprecision, the other parameters achieved this target
in most XN-modules.
Analyzers harmonization
The mean values of the CPD parameters
obtained in each group of samples are shown in
Tables II, III, IV and Figures 1, 2 and 3. Albeit a good
agreement was found among the different XN-mod-
ules (maximum 4.0% Bias, except for NE, LY and
MO-WZ), the median values were significantly differ-
ent using both Kruskal-Wallis test and ANOVA, except
for NE-WX, LY-WY, MO-WY.
The alignment was also assessed using intra-
individual biological variation data (i.e., CVI). The
MO-WY parameter displayed a Bias% lower than the
BALG% obtained from biological variation (0.33*CVI)
(15) in all XN–Modules (Table II, III, IV). The compar-
ison between the target BALG% and BAPS% (14)
showed a significant difference (i.e., lack of overlap
between 95% CIs) for only the NE-SSC, NE-FCS, NE-
WX, LY-WX and LY-WY parameters.
Notably, the median values of the CPD-parame-
ters were not significantly different between the group
of 30 healthy blood donors and the MA population.
Nevertheless, the relative B% recorded for each XN-
module using control blood (i.e., containing stabilized
cells) was found to be similar to that observed using
fresh blood (i.e., obtained from the 30 healthy blood
donors and the MA population). The median values
of the CPD parameters were found to be similar to
those obtained in a subsequent study, which was
repeated two months later using additional fresh
blood from 30 healthy blood donors and the MA
population. These data attest that CPD-parameters
may be quite stable over time. 
The IAF was then calculated for each CPD
parameter, and for each of the five XN-modules.
When all CPD data were adjusted for the instrument-
specific IAF calculated from the MA population, the
mean values were no longer statistically different
among the five XN-modules, as shown in Figures 1,
2 and 3. In this case, the Bias% of all parameters for
each XN-module was found to be lower than the
BALG%.
Data adjustment for instrument-specific IAF cal-
culated from the results obtained on blood collected
from 30 healthy blood donors confirmed the data,
thus obtaining the same effective harmonization
(data not shown). Identical results were obtained
when the identical study was repeated two months
afterward, thus suggesting that IAF should only be
calculated on data generated from an MA population.
Assessment of blood sample stability 
The different CPD-parameters displayed hetero-
geneous stability, mostly depending on the storage
temperature (Table VI). Overall, lower stability was
observed in samples stored at 4 °C. More specifically,
2 hours storage at 4 °C was already sufficient to
impair the assessment of NE-FSC, NE-WX and MO-
X, whilst NE-SSC, NE-SFL, NE-WY, LY-Y, LY-WY, MO-
Z and MO-WY were found to be stable for at least 8
hours, regardless of the storage temperature. Sample
storage at 4 °C for 2 hours generated a B% higher
than the analytical performance specification for Bias
(BAPS) (14) for all parameters except NE-SFL, LY-Y, LY-
WY, and MO-WY. Nevertheless, the %B of all para m -
eters remained always lower than the RCV in all
samples stored for up to 8 hours at both storage tem-
peratures.
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Table I Within-run imprecision CPD parameters: the mean value (ch) and %CV, obtained from 10 replicates of five aliquots of a healthy
subject, are shown and compared CVAPS (14).
Legend: CVAPS: analytical performance specification for imprecision for desirable level; highlighted in grey: the imprecision does not
meet the analytical goal for minimum performance.
XN-A XN-B XN-C XN-D XN-E
CVAPS%
(95%CI) (14)
NE–SSC
(ch)
Mean (95%CI) 151.8 (151.2–152.3) 150.9 (150.2–151.5) 150.3 (150.0–150.7) 148.1 (147.5–148.7) 148.3 (147.8–148.9)
%CV (95%CI) 0.5 (0.3–0.9) 0.6 (0.4–1.0) 0.4 (0.2–0.6) 0.6 (0.4–1.0) 0.5 (0.4–1.0) 0.3 (0.2–0.4)
NE–SFL
(ch)
Mean (95%CI) 49.6 (49.3–49.9) 50.6 (50.2–50.9) 51.4 (51.2–51.7) 48.2 (47.7–48.6) 50.1 (49.8–50.3)
%CV (95%CI) 0.8 (0.6–1.5) 1.0 (0.7–1.9) 0.7 (0.5–1.4) 1.2 (0.8–2.2) 0.7 (0.5–1.3) 1.3 (1.1–1.5)
NE–SFC
(ch)
Mean (95%CI) 93.1 (92.3 to 94.0) 92.8 (91.9–93.7) 93.9 (92.8–94.9) 95.6 (94.3–96.8) 95.5 (94.5–96.4)
%CV (95%CI) 1.3 (0.9–2.4) 1.4 (0.9–2.5) 1.5 (1.0–27) 1.8 (1.2–3.2) 1.4 (1.0–2.5) 0.6 (0.5–0.7)
LY–X
(ch)
Mean (95%CI) 75.8 (75.4–76.2) 76.6 (76.3–77.0) 74.3 (73.8–74.7) 76.4 (76.1–76.7) 76.1 (75.7–76.6)
%CV (95%CI)) 0.8 (0.5–1.4) 0.7 (0.5–1.2) 0.8 (0.6–1.5) 0.5 (0.4–0.9) 0.8 (0.5–1.4) 0.9 (0.8–1.1)
LY–Y
(ch)
Mean (95%CI) 71.7 (70.7 to 72.6) 73.0 (72.2–73.9) 74.6 (74.0–75.2) 69.9 (69.4–70.4) 71.9 (71.2–72.6)
%CV (95%CI) 1.8 (1.2–3.3) 1.6 (1.1–3.0) 1.2 (0.8–2.2) 1.1 (0.7–2) 1.3 (0.9–2.4) 1.2 (1.0–1.4)
LY–Z
(ch)
Mean (95%CI) 58.9 (58.1–59.6) 58.8 (58.4–59.2) 556.9 (56.5–57.2) 59.5 (59.1–59.9) 62.3 (61.7–62.9)
%CV (95%CI) 1.7 (1.2–3.1) 0.9 (0.6–1.6) 0.8 (0.6–1.5) 0.9 (0.6–1.7) 1.3 (0.9–2.4) 0.8 (0.7–1.0)
MO–X
(ch)
Mean (95%CI) 116.4 (115.6–117.2) 117.1 (116.2–117.9) 114.5 (113.8–115.1) 114.9 (114.1–115.7) 115.2 (114.4–116.0)
%CV (95%CI) 1.0 (0.7–1.8) 0.9 (0.7–1.9) 0.8 (0.6–1.5) 1.0 (0.7–1.7) 1.0 (0.7–1.7) 0.5 (0.4–0.7)
MO–Y
(ch)
Mean (95%CI) 103.4 (99.7–107.2) 106.1 (102.1–110.1) 109.7 (106.9–112.6) 101.2 (98.0–104.4) 104.2 (102.0–106.4)
%CV (95%CI) 5.1 (3.5–9.3) 5.3 (3.7–9.7) 3.7 (2.5–6.7) 4.5 (3.1–8.1) 3.0 (2–5.4) 1.3 (1.0–1.7)
MO–Z
(ch)
Mean (95%CI) 68.7 (68.0–69.4) 66.1 (65.2–67.0) 66.3 (64.8–67.8) 65.4 (64.6–66.2) 69.3 (62.0–70.6)
%CV (95%CI) 1.4 (1–2.6) 1.9 (1.3–3.5) 3.1 (2.1–5.7) 1.7 (1.2–3.1) 2.6 (1.8–4.8) 0.5 (0.0–0.8)
NE–WX
(ch)
Mean (95%CI) 297.2 (285.6–308.8) 309.0 (297.8–320.2) 313.4 (304.7–322.1) 316.6 (305.7–327.5) 304.7 (295.5–313.9)
%CV (95%CI) 5.5 (3.8–10.0) 5.1 (3.5–9.2) 3.9 (2.7–7.1) 4.8 (3.3–8.8) 4.2 (2.9–7.7) 0.7 (0.5–1.0)
NE–WY
(ch)
Mean (95%CI) 576.9 (559.9–593.4) 575.6 (553.2–598.0) 571.4 (554.3–588.5) 573.3 (560.3–586.3) 563.5 (544.5–582.5)
%CV (95%CI) 4.1 (2.8–7.5) 5.4 (3.7–9.9) 4.2 (2.9–7.6) 3.2 (2.2–5.8) 4.7(3.2–8.6) 0.9 (0.5–1.2)
NE–WZ
(ch)
Mean (95%CI) 782.7 (769.5–795.9) 668.2 (642.9–693.5) 616.9 (603.1–630.7) 600.8 (578.1–623.5) 744.7 (734.5–754.9)
%CV (95%CI) 2.4 (1.6–4.3) 5.3 (3.6–9.6) 3.1 (2.2–5.7) 5.3 (3.6–9.6) 1.9 (1.3–3.5) 0.7 (0.0–1.1)
LY–WX
(ch)
Mean (95%CI) 539.7 (507.9–571.5) 502.2 (470.9–533.5) 512.9 (496.2–529.6) 509.4 (493.3–525.5) 530.5 (507.7–553.3)
%CV (95%CI) 8.2 (5.7–15) 8.7 (6.0–15.7) 4.5 (3.1–10.2) 4.4 (3.0–8.1) 6.0 (4.1–11.0) 2.0 (1.4–2.7)
LY–WY
(ch)
Mean (95%CI) 797.0 (763.8–830.2) 786.8 (762.7–810.9) 815.8 (785.6–846.0) 802.4 (775.8–829.0) 838.7 (812.9–864.5)
%CV (95%CI) 5.8 (4.0–10.6) 4.3 (2.9–7.8) 5.2 (3.6–9.4) 4.6 (3.2–8.5) 4.3 (3–7.8) 1.0 (0.0–1.6)
LY–WZ
(ch)
Mean (95%CI) 718.6 (694.7–742.5) 615.6 (599.6–631.6) 581.9 (566.1–597.7) 507.8 (494.1–521.5) 617.7 (605.4–629.9)
%CV (95%CI) 4.6 (3.2–8.5) 3.6 (2.5–6.6) 3.8 (2.6–7) 3.8 (2.6–6.9) 2.8 (1.9–5.1) 1.3 (1.0–1.7)
MO–WX
(ch)
Mean (95%CI) 258.7 (249.3–268.0) 256.1 (245.6–266.6) 238.5 (230.3–246.7) 243.7 (233.4–254.0) 235.2 (226.1–244.3)
%CV (95%CI) 5.0 (3.5–9.2) 5.7 (3.9–10.5) 4.8 (3.3–8.9) 5.9 (4.1–10.8) 5.4 (3.7–9.8) 2.1 (1.1–2.9)
MO–WY
(ch)
Mean (95%CI) 676.8 (608.6–745.0) 652.0 (593.4–710.6) 655.8 (622.9–688.7) 694.2 (642.6–745.8) 666.4 (626.4–706.4)
%CV (95%CI) 14.1 (9.7–25.7) 12.6 (8.6–22.9) 7 (4.8–12.8) 10.4 (7.1–19) 8.4 (5.8–15.3) 2.5 (0.9–3.6)
MO–WZ
(ch)
Mean (95%CI) 805.9 (766.4–845.3) 690.2 (645.3–735.1) 657.0 (603.1–710.9) 672.6 (617.3–727.9) 747.5 (713.9–781.1)
%CV (95%CI) 6.8 (4.7–12.5) 9.1 (6.3–16.6) 11.5 (7.9–20.9) 11.5 (7.9–21) 6.3 (4.3–11.5) 1.6 (1.0–2.5)
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30 healthy blood donors 
November 2015
Moving Average 
November 2015
XN-Check (Normal level) 
November 2015 BAPS%
(95%CI)
BALG%
(95%CI)Median
(95%CI)
Bias% vs OVM
(95%CI)
N 
samples
Median 
(95%CI)
Bias% vs OVM
(95%CI)
Median 
(95%CI)
Bias% vs OVM
(95%CI)
NE-SSC 
(ch) 
§¥
XN-A 152.15(150.70/154.59)
1.22 
(1.208/1.239) 1426
152.10
(151.9/152.4)
1.14
(1.139/1.142)
170.05
(169.80/170.30)
1.18
(1.178/1.182)
0.60
(0.50/0.90)
0.20
(0.16/0.23)
XN-B 149.20(147.50/151.80)
-0.75
(-0.741/-0.763) 1555
149.40
(149.10/149.70)
-0.65
(-0.649/-0.651)
166.95
(166.80/167.10)
-0.66 
(-0.659/-0.661)
XN-C 151.60(149.30/153.50)
0.85
(0.837-0.861) 1687
151.10
(151.0/151.3)
0.48
(0.480/0.481)
168.80
(168.60/169.0)
0.44
(0.439/0.441)
XN-D 149.70(147.20/151.40)
-0.41
(-0.403/ -0.415) 1124
150.00
(149.6/150.3)
-0.25
(-0.249/-0.251)
167.40
(167.30/167.60)
-0.39
(-0.389/-0.391)
XN-E 148.95(146.90/150.60)
-0.91
(-0.897/-0.920) 910
149.30
(148.8/149.6)
-0.72
(-0.718/-0.721)
167.10
(166.90/167.20)
-0.57
(-0.569/-0.570)
OVM 150.32(148.32/152.36)
150.38
(150.08/150.66)
168.06
(167.88/168.24)
NE-SFL
(ch)
§¥
XN-A 50.05(48.50/50.80)
0.72 
(0.698/0.731) 1426
49.30
(49.10/49.50)
1.07
(1.066/1.074)
99.70
(99.20/100.20)
1.23
(1.224/1.236)
1.10
(0.90/1.50)
0.90
(0.76/1.02)
XN-B 48.85(47.50/50.00)
-1.69
(-1.643/-1.730) 1555
48.40
(48.30/48.60)
-0.78
(-0.778/-0.783)
95.75
(95.40/96.90)
-2.78
(-2.770/-2.813)
XN-C 50.90(49.10/51.50)
2.44 
(2.354/2.469) 1687
50.60
(50.50/50.70)
3.73
(3.723/3.737)
102.50
(102.30/103.60)
4.07
(4.062/4.114)
XN-D 48.30 (46.90/48.70)
-2.80
(-2.719/-2.823) 1124
46.90
(46.70/47.10)
-3.85
(-3.834/-3.866)
97.00
(96.70/97.30)
-1.51
(-1.505/-1.515)
XN-E 50.35(49.00/51.40)
1.33
(1.294/1.358) 910
48.70
(48.50/48.80)
-0.16
(-0.159/-0.160)
97.50
(97.20798.00)
-1.01
(-1.007/-1.015)
OVM 49.69(48.20/50.48)
48.78
(48.62/48.94)
98.49
(98.16/99.20)
NE-FCS
(ch)
§¥ 
XN-A 90.90(89.10/92.20)
0.69 
(0.676/0.700) 1426
89.60
(89.30/89.80)
0.43
(0.429/0.431)
124.95
(124.20/125.30)
0.85
(0.845/0.852)
0.80
(0.60/1.10)
0.40
(0.33/0.50)
XN-B 89.05(87.60/89.70)
-1.36
(-1.338/-1.370) 1555
87.70
(87.60/88.00)
-1.70
(-1.698/-1.706)
120.45
(119.60/121.10)
-2.78
(-2.760/-2.795)
XN-C 88.75(87.30/89.70)
-1.69
(-1.662/-1.708) 1687
88.30
(88.10/88.50)
-1.03
(-1.028/-1.032)
123.50
(123.10/123.80)
-0.32
(-0.319/-0.321)
XN-D 91.00(89.70/92.40)
0.80 
(0.789/0.812) 1124
90.40
(90.20/90.60)
1.32
(1.317/1.323)
125.30
(124.90/125.60)
1.13
(1.126/1.133)
XN-E 91.70(89.80/92.70)
1.57
(1.537/1.587) 910
90.10
(89.90/90.40)
0.99
(0.988/0.993)
125.30
(125.00/125.60)
1.13
(1.127/1.133)
OVM 90.28(88.70/91.34)
89.22
(89.02/89.46)
123.90
(123.36/124.28)
NE-WX
(ch)
XN-A 314.00(309.00/320.00)
1.00 
(0.984/1.019) 1426 
312.00
(311.00/313.00)
1.01
(1.007/1.013)
332.00
(332.00/339.00)
1.02
(1.020/1.042)
0.80
(0.60/1.20)
0.40
(0.00/0.66)
XN-B 316.00(312.00/320.00)
1.00 
(0.987/1.013) 1555 
319.00
(318.00/319.00)
0.99
(0.987/0.990)
341.50
(336.00/342.00)
0.99
(0.974/0.991)
XN-C 320.50(311.00/323.00)
0.98
(0.951/0.988) 1687 
317.00
(316.00/318.00)
1.00
(0.997/1.003)
343.00
(337.00/343.00)
0.99
(0.973/0.990)
XN-D 314.00(309.00/324.00)
1.00
(0.984/1.032) 1124 
317.00
(316.00/318.00)
1.00
(0.997/1.003)
340.50
(335.00/341.00)
1.00
(0.984/1.001)
XN-E 309.00(303.00/323.00)
1.02
(1.000/1.066) 910 
314.00
(312.00/315.00)
1.01
(1.004/1.013)
340.00
(335.00/340.00)
1.00
(0.985/1.000)
OVM 314.70(308.80/322.00)
315.80
(314.60/316.60)
339.30
(335.00/341.00
NE-WY
(ch)
§¥
XN-A 592.00(580.00/596.00)
1.01 
(0.990/1.017) 1426 
585.00
(584.00/587.00)
1.00
(0.998/1.003)
668.50
(652.00/679.00)
1.00
(0.975/1.016)
0.50
(0.30/0.80)
0.60
(0.33/0.81)
XN-B 591.00(582.00/600.00)
1.01
(0.995/1.025) 1555 
591.00
(589.00/592.00)
0.99
(0.987/0.992)
670.50
(655.00/686.00)
1.00
(0.977/1.023)
XN-C 591.00(577.00/605.00)
1.01
(0.986/1.034) 1687 
588.00
(586.00/590.00)
1.00
(0.997/1.003)
663.00
(648.00/678.00)
1.01
(0.987/1.033)
XN-D 602.50(599.00/613.00)
0.99
(0.984/1.007) 1124 
594.00
(592.00/596.00)
0.99
(0.987/0.993)
666.50
(653.00/672.00)
1.00
(0.980/1.008)
XN-E 604.00(588.00/610.00)
0.99
(0.964/1.000) 910 
579.00
(577.00/581.00)
1.01
(1.007/1.013)
669.00
(649.00/677.00)
1.00
(0.970/1.012)
OVM 596.10(585.20/604.80)
587.40
(585.60/589.20)
667.60
(651.40/678.40)
NE-WZ
(ch)
§¥
XN-A 793.50(785.00/802.00)
8.80
(8.706/8.894) 1426
786.00
(785.00/789.00)
9.62
(9.608/9.657)
835.00
(828.00/849.00)
-1.66
(-1.649/-1.691)
0.60
(0.30/1.00)
0.50
(0.00/0.73)
XN-B 740.50(727.00/753.00)
1.53
(1.502/1.556) 1555
727.00
(725.00/730.00)
1.39
(1.386/1.396)
849.00
(822.00/859.00)
7.33
(7.093/7.412)
XN-C 676.00(666.00/697.00)
-7.30
(-7.192/-7.527) 1687
671.00
(669.00/673.00)
-6.42
(-6.401/-6.439)
789.00
(769.00/805.00)
6.68
(6.510/6.815)
XN-D 636.00(613.00/650.00)
-12.79
(-12.327/-13.072) 1124
627.00
(625.00/629.00)
-12.55
(-12.51/-12.590)
738.00
(723.00/757.00)
-18.73
(-18.348/-19.211)
XN-E 800.50(782.00/821.00)
9.76
(9.534/10.010) 910
774.00
(770.00/776.00)
7.95
(7.909/7.971)
890.50
(881.00/916.00)
8.21
(8.119/8.442)
OVM 729.30(714.60/744.60)
717.00
(714.80/719.40)
820.30
(804.6/837.2)
Table II Analyzers harmonization: lymphocytes cell population data. The median value and relative Bias (%) (calculated with respect to overall median
[OMV]) of lymphocytes cell population data parameters to BAPS% (14) and target alignment Bias proposed by Fraser et al. (0.33×CVI) (BALG%) (15).
§: comparison of median value of CPD parameter evaluated for all 5 XN showed a significative difference in all pair comparisons by Kruskal-Wallis test with p<0.0001 in all
groups of samples; ¥: comparison of mean value of CPD parameter evaluated for all 5 XN showed a significative difference on ANOVA with p<0.0001 in all groups of samples.
Highlighted in grey: Bias% is lower than the BALG%. BALG: alignment bias based on intra-individual biological variation; BAPS: analytical performance specification for Bias%;
NE-FSC: neutrophil cell size; NE-SFL: neutrophil fluorescence intensity; NE-SSC: neutrophil cell complexity; NE-WX: neutrophil complexity and width of dispersion of the events
measured; NE-WY: neutrophils fluorescence intensity and the width of dispersion; NE-WZ: neutrophil cell size and the width of dispersion; OMV: overall median.
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Table III Analyzers harmonization: lymphocytes cell population data. The median value and relative Bias (%) (in respect to overall median [OMV]) of lym-
phocytes cell population data parameters compared in respect to BAPS% (14) and target alignment Bias proposed by Fraser et al. (0.33×CVI) (BALG%) (15).
30 healthy blood donors 
November 2015
Moving Average 
November 2015
XN-Check (Normal level) 
November 2015 BAPS%
(95%CI)
BALG%
(95%CI)Median
(95%CI)
Bias% vs OVM
(95%CI)
N 
samples
Median
(95%CI)
Bias% vs OVM
(95%CI)
Median
(95%CI)
Bias% vs OVM
(95%CI)
LY-X 
(ch) 
§¥
XN-A 78.45(77.50/78.90)
1.76
(1.739/1.770) 1426
77.60
(77.50/77.70)
2.05
(2.047/2.053)
86.65
(86.10/87.00)
0.36
(0.358/0.361)
0.70
(0.50/0.90)
0.60
(0.53/0.73)
XN-B 76.50(76.00/76.80)
-0.77
(-0.765/-0.773) 1555
75.50
(75.30/75.60)
-0.71
(-0.708/-0.711)
85.80
(85.50/86.30)
-0.14 
(-0.140/-0.141)
XN-C 75.75(75.20/76.60)
-1.74
(-1.727/-1.760) 1687
75.20
(75.10/75.20)
-1.10
(-1.099/-1.100)
85.50
(85.40/85.80)
-0.32
(-0.320/-0.321)
XN-D 77.35(76.50/77.90)
0.34
(0.336/0.342) 1124
75.80
(75.70/76.00)
-0.32
(-0.320/-0.321)
86.25
(85.80/86.50)
0.12
(0.119/0.120)
XN-E 77.40(76.80/77.70)
0.40
(0.397/0.402) 910
76.10
(75.90/76.20)
0.08
(0.080/0.080)
86.00
(85.50/86.50)
-0.02
(-0.020/-0.020)
OVM 77.09(76.40/77.58)
76.04
(75.90/76.14)
86.04
(85.66/86.42)
LY-Y 
(ch) 
§¥
XN-A 71.95(70.50/73.20)
0.63
(0.617/0.641) 1426
72.00
(71.90/72.20)
1.21
(1.208/1.213)
67.75
(67.40/68.20)
-0.53
(-0.527/-0.534)
0.80
(0.60/1.10)
0.76
(0.63/0.92)
XN-B 70.45(69.50/71.40)
-1.40
(-1.381/-1.419) 1555
70.50
(70.40/70.80)
-0.90
(-0.899/-0.904)
66.40
(66.00/66.809
-2.51
(-2.495/-2.525)
XN-C 72.70(71.10/74.10
1.68
(1.643/1.712) 1687
73.80
(73.60/73.90)
3.74
(3.730/3.745)
70.60
(70.20/70.80)
3.66
(3.639/3.670)
XN-D 70.10(69.00/70.50)
-1.96
(-1.929/-1.971) 1124
68.90
(68.70/69.10)
-3.15
(-3.141/-3.159)
67.60
(67.20/68.00)
-0.75 
(-0.746/-0.754)
XN-E 72.30(71.50/73.10)
1.12
(1.108/1.132) 910
70.50
(70.40/70.80)
-0.90
(-0.899/-0.904)
68.20
(67.90/68.40)
0.13
(0.129/0.130)
OVM 71.50(70.32/72.46)
71.14
(71.00/71.36)
68.11
(67.74/68.44)
LY-Z 
(ch) 
§¥
XN-A 59.60(58.70/60.00)
1.60
(1.576/1.611) 1426
59.80
(59.70/59.80)
1.98
(1.977/1.980)
91.35
(90.80/91.80)
-1.53
(-1.521/-1.538)
0.50
(0.40/0.60)
0.53
(0.43/0.63)
XN-B 58.15(57.80/58.60)
-0.87
(-0.865/-0.877) 1555
58.20
(58.10/58.20)
-0.75
(-0.749/-0.750)
90.70
(90.00/91.20)
-2.23
(-2.213/-2.242)
XN-C 55.75(55.40/55.90)
-4.96
(-4.929/-4.973) 1687
56.50
(56.40/56.60)
-3.65
(-3.644/-3.656)
90.90
(90.70/91.40)
-2.02
(-2.016/-2.031)
XN-D 58.20(57.60/58.50)
-0.78
(-0.772/-0.784) 1124
58.10
(58.00/58.20)
-0.92
(-0.918/-0.922)
95.80
(95.40/96.30)
3.27
(3.256/3.287)
XN-E 61.60(61.40/62.40)
5.01
(4.994/5.075) 910
60.60
(60.50/60.80)
3.34 
(3.334/3.351)
95.10
(94.70/95.40)
2.51
(2.499/2.518)
OVM 58.66(58.18/59.08)
58.64
(58.54/58.72)
92.77
(92.32/93.22)
LY-WX 
(ch) 
§¥
XN-A 518.00(505.00/523.00)
3.02
(2.944/3.049) 1426
519.0
(515.00/521.00)
1.65
(1.637/1.656)
703.00
(699.00/708.00)
-1.99
(-1.979/-2.004)
1.80
(1.30/2.70)
1.32
(0.91/1.75)
XN-B 503.50(478.00/527.00)
0.14
(0.133/0.147) 1555
509.0
(515.00/521.00)
-0.31
(-0.308/-0.311)
715.50
(708.00/725.00)
-0.76
(-0.752/-0.770)
XN-C 520.00(490.00/546.00)
3.42
(3.223/3.591) 1687
518.0
(506.00/511.00)
1.45
(1.442/1.458)
729.00
(724.00/734.00)
2.05
(2.036/2.064)
XN-D 478.50(470.00/492.00)
-4.83
(-4.744/-4.966) 1124
505.00
(515.00/521.00)
-1.10
(-1.093/-1.107)
721.50
(716.00/726.00)
0.10
(0.099/0.101)
XN-E 494.00(466.00/506.00)
-1.75
(-1.651/-1.793) 910
502.00
(502.00/508.00)
-1.68
(-1.670/-1.693)
725.00
(720.00/730.00)
0.60
(0.596/0.604)
OVM 502.80(481.80/518.80)
510.60
(507.40/513.40)
705.20
(713.40/724.60)
LY-WY
(ch)
XN-A 844.00(806.00/871.00)
1.01
(0.965/1.042) 1426
851.00
(847.00/855.00)
1.01
(1.005/1.015)
699.00
(688.00/719.00)
1.04
(1.024/1.070)
1.30
(0.80/1.90)
0.66
(0.00/2.97)
XN-B 867.00(827.00/883.00)
0.98 
(0.935/0.998) 1555
865.00
(859.00/868.00)
1.00
(0.993/1.003)
751.50
(721.00/758.00)
0.97
(0.931/0.978)
XN-C 845.00(816.00/874.00)
1.01
(0.975/1.045) 1687
863.00
(860.00/867.00)
1.00
(0.997/1.005)
720.00
(713.00/754.00)
1.01
(1.000/1.058)
XN-D 855.00(838.00/878.00)
1.00 
(0.980/1.027) 1124
878.00
(872.00/883.00)
0.98
(0.973/0.986)
750.50
(739.00/768.00)
0.97
(0.955/0.993)
XN-E 857.00(829.00/879.00)
1.00 
(0.967/1.026) 910
857.00
(851.00/861.00)
1.01
(1.003/1.015)
715.00
(710.00/744.00)
1.02
(1.013/1.061)
OVM 853.60(823.20/877.00)
862.80
(857.80/866.80)
727.20
(714.20/748.60)
LY-WZ
(ch)
§¥
XN-A 691.00(679.00/715.00)
14.06
(13.816/14.548) 1426
705.00
(704.00/708.00)
13.16
(13.141/13.216)
741.00
(726.00/751.00)
3.88
(3.801/3.932)
0.70
(0.50/1.10)
0.87
(0.64/1.12)
XN-B 612.50(605.00/621.00)
1.10
(1.087/1.115) 1555
632.00
(630.00/633.00)
1.44
(1.435/1.442)
715.50
(704.00/723.00)
0.76
(0.748/0.768)
XN-C 595.00(586.00/608.00)
-1.78
(-1.753/-1.819) 1687
594.0
(592.00/595.00)
-4.65
(-4.634/-4.658)
680.00
(669.00/692.00)
-3.24
(-3.188/-3.297)
XN-D 511.50(502.00/528.00)
-15.56
(-15.271/-16.062) 1124
540.00
(538.00/543.00)
-13.32
(-13.271/-13.394)
657.00
(650.00/668.00)
-7.16
(-7.084/-7.280)
XN-E 619.00(605.00/630.00)
2.18
(2.131/2.219) 910
644.00
(642.00/647.00)
3.37
(3.360/3.386)
749.00
(739.00/761.00)
5.76
(5.683/5.852)
OVM 605.80(595.40/620.40)
628.33
(621.20/625.20)
681.73
(697.60/719.00)
§: comparison of mean value of CPD parameter evaluated for all 5 XN showed a significant difference in all pair comparisons by Kruskal-Wallis test with p<0.0001 in all groups
of samples; ¥: comparison of mean value of CPD parameter evaluated for all 5 XN showed a significative difference on ANOVA with p<0.0001 in all groups of samples. Highlighted
in grey: Bias% is lower than the BALG%. BALG: alignment bias based on intra-individual biological variation; BAPS: analytical performance specification for Bias; LY-WX: lymphocyte
complexity and width of dispersion of the events measured; LY-WY: lymphocyte fluorescence intensity and the width of dispersion; LY-WZ: lymphocyte cell size and the width of dis-
persion; LY-X: lymphocyte cell complexity; LY-Y: lymphocyte fluorescence intensity; LY-Z: lymphocyte cell size; OMV: overall median.
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Table IV Analyzers harmonization: monocytes cell population data. The median value and relative Bias (%) (calculated in respect to overall median
[OMV]) of monocytes cell population data parameters to BAPS% (14) and target alignment Bias proposed by Fraser et al. (0.33×CVI) (BALG%) (15).
30 healthy blood donors 
November 2015
Moving Average 
November 2015
XN-Check (Normal) 
November 2015 BAPS %
(95%CI)
BALG % 
(95%CI)Median
(95%CI)
Bias% vs OVM
(95%CI)
N 
samples
Median
(95%CI)
Bias% vs OVM
(95%CI)
Median
(95%CI)
Bias% vs OVM
(95%CI)
MO-X
(ch)
§¥
XN-A 118.90(118.3/119.4)
2.26
(2.249/2.270) 1426
119.20
(119.10/119.30)
2.09
(2.088/2.092)
129.15
(127.80/130.80)
-0.02 
(-0.020/-0.020)
0.40
(0.30/0.50)
0.36
(0.30/0.46)
XN-B 115.45(114.7/115.7)
-0.71
(-0.705/-0.712) 1555
116.00
(115.90/116.10)
-0.65
(-0.649/-0.651)
129.30
(128.90/130.40)
0.09
(0.090/0.091)
XN-C 115.65(115.0/116.3)
-0.53
(-0.527/-0.533) 1687
116.60
(116.50/116.70)
-0.14
(-0.139/-0.140)
129.20
(128.80/129.90)
0.02
(0.019/0.020)
XN-D 115.45(114.90/116.00)
-0.71
(-0.707/-0.713) 1124
115.90
(115.80/116.00)
-0.74
(-0.739/-0.741)
129.55
(128.90/130.00)
0.29
(0.289/0.291)
XN-E 115.90(114.90/116.30)
-0.32
(-0.317/-0.321) 910
116.10
(116.00/116.20
-0.57
(-0.569/-0.570)
128.70
(128.40/129.70)
-0.37 
(-0.369/-0.373)
OVM 116.27(115.60/116.70)
116.76
(116.66/116.86)
129.18
(128.56/130.16)
MO-Y 
(ch)
§¥
XN-A 113.25(112.10/116.30)
1.13
(1.119/1.160) 1426
115.20
(114.80/115.60)
1.53
(1.525/1.535)
124.30
(121.80/126.00)
-0.15 
(-0.147/-0.152)
0.80
(0.60/1.20)
0.86
(0.66/1.09)
XN-B 110.05(108.40/111.50)
-1.72
(-1.694/-1.743) 1555
112.00
(111.60/112.30)
-1.29
(-1.285/-1.293)
120.70
(120.20/122.50)
-3.04 
(-3.027/-3.085)
XN-C 114.95(113.60/117.20)
2.65
(2.619/2.702) 1687
118.30
(118.00/118.60)
4.27
(4.259/4.281)
129.50
(129.00/131.50)
4.02
(4.004/4.082)
XN-D 108.50(106.50/112.20)
-3.11
(-3.053/-3.216) 1124
109.70
(109.20/110.10)
-3.31
(-3.295/-3.322)
123.65
(123.00/125.00)
-0.67
(-0.666/-0.677)
XN-E 113.15(110.70/115.30)
1.04
(1.017/1.060) 910
112.10
(111.80/112.40)
-1.20
(-1.197/-1.203)
124.30
(123.80/125.00)
-0.15
(-0.149/-0.151)
OVM 111.98(110.30/114.50)
113.46
(113.08/113.80)
124.49
(123.56/126.00)
MO-Z 
(ch)
§¥
XN-A 68.50(67.40/69.10)
4.13
(4.064/4.166) 1426
68.50
(68.30/68.60)
4.93
(4.916/4.937)
105.00
(103.50/106.20)
-0.58
(-0.572/-0.587)
0.50
(0.30/0.70)
0.33
(0.00/0.53)
XN-B 64.90(64.50/65.20)
-1.34
(-1.332/-1.346) 1555
64.60
(64.50/64.80)
-1.04
(-1.038/-1.043)
104.25
(103.30/105.30)
-1.29
(-1.278/-1.303)
XN-C 63.80(63.00/64.50)
-3.01
(-2.972/-3.043) 1687
64.30
(64.20/64.40)
-1.50
(-1.498/-1.502)
105.10
(103.30/105.30)
-0.48
(-0.475/-0.485)
XN-D 63.40(63.20/64.10)
-3.62
(-3.609/-3.660) 1124
62.60
(62.50/62.70)
-4.11
(-4.103/-4.117)
107.10
(106.60/107.80)
1.41
(1.403/1.419)
XN-E 68.30(67.80/68.80)
3.83
(3.802/3.858) 910
66.40
(66.20/66.60)
1.72
(1.715/1.725)
106.60
(104.80/107.60)
0.94
(0.924/0.949)
OVM 65.78(65.18/66.34)
65.28
(65.14/65.42)
105.61
(104.46/106.64)
MO-WX
(ch)
§¥
XN-A 264.50(258.00/274.00)
5.00
(4.877/5.180) 1426
263.00
(262.00/265.00)
3.46
(3.447/3.486)
383.00
(379.00/391.00)
4.41
(4.364/4.502)
1.10
(0.50/1.70)
1.39
(0.73/1.94)
XN-B 247.00(241.00/258.00)
-1.94
(-1.893/-2.026) 1555
251.00
(250.00/252.00)
-1.26
(-1.255/-1.265)
359.50
(356.00/362.00)
-0.71
(-0.703/-0.715)
XN-C 248.00(242.00/251.00)
-1.55
(-1.513/-1.569) 1687
253.00
(252.00/255.00)
-0.47
(-0.468/-0.474)
375.00
(368.00/379.00)
2.11
(2.071/2.133)
XN-D 250.50(244.00/255.00)
-0.56
(-0.545/-0.570) 1124
254.00
(253.00/256.00)
-0.08
(-0.079/-0.081
361.00
(355.00/364.00)
-3.25
(-3.196/-3.277)
XN-E 249.50(241.00/258.00)
-0.95
(-0.918/-0.982) 910
250.00
(249.00/252.00)
-1.65
(-1.643/-1.663)
365.50
(360.00/370.00)
-2.57
(-2.531/-2.602)
OVM 251.90(245.20/259.20)
254.20
(253.20/256.00)
354.52
(363.60/373.20)
MO-WY
(ch)
XN-A 677.00(643.00/690.00)
0.99
(0.940/1.009) 1426
674.00
(667.00/678.00)
1.00
(0.990/1.006)
873.00
(844.00/905.00)
0.96 
(0.928/0.995)
1.60
(0.70/2.60)
1.60
(0.54/2.38)
XN-B 636.50(611.00/692.00)
1.05
(1.008/1.142) 1555
672.00
(668.00/677.00)
1.00
(0.994/1.007)
818.00
(792.00/867.00)
1.03
(0.997/1.092)
XN-C 665.00(637.00/715.00)
1.01
(1.008/1.142) 1687
666.00
(662.00/673.00)
1.01
(1.004/1.021)
859.00
(824.00/882.00)
0.98 
(0.940/1.006)
XN-D 690.50(636.00/761.00)
0.97
(0.967/1.086) 1124
674.00
(668.00/681.00)
1.00
(0.991/1.010)
857.50
(806.00/859.00)
0.98
(0.921/0.982)
XN-E 677.50(639.00/708.00)
0.99
(0.893/1.069) 910
677.00
(670.00/683.00)
0.99
(0.980/0.999)
800.00
(800.00/839.00)
1.05
(1.050/1.101)
OVM 669.30(633.20/713.20)
672.60
(667.00/678.40)
841.50
(813.20/870.40)
MO-WZ
(ch)
§¥
XN-A 789.00(750.0/818.00)
12.28
(11.673/12.731 1426
779.00
(774.00/782.00)
10.87
(10.800/10.912)
880.00
(858.00/894.00)
4.82
(4.700/4.897)
1.10
(0.70/1.80)
1.06
(0.00/1.60)
XN-B 683.00(667.00/708.00)
-2.80
(-2.734/-2.902) 1555
697.00
(694.00/699.00)
-0.80
(-0.797/-0.802)
813.50
(794.00/840.00)
-3.66
(-3.572/-3.779)
XN-C 653.50(625.00/669.00)
-7.00
(-6.695/-7.166) 1687
643.00
(639.00/646.00)
-8.48
(-8.427/-8.520)
792.00
(776.00/806.00)
-4.02
(-3.939/-4.091)
XN-D 625.00(611.00/650.00)
-11.06
(-10.812/-11.502) 1124
624.00
(620.00/630.00)
-11.19
(-11.118/-11.298)
773.00
(765.00/789.00)
-8.48
(-8.392/-8.656)
XN-E 763.00(743.00/793.00)
8.58
(8.355/8.917) 910
770.00
(762.00/776.00)
9.59
(9.490/9.665)
941.50
(919.00/954.00)
11.33
(11.059/11.480)
OVM 702.70(679.20/727.60)
702.60
(697.80/706.60)
784.50
(822.40/856.60)
§: comparison of mean value of CPD parameter evaluated for all 5 XN showed a significant difference in all pair comparisons by Kruskal-Wallis test with p<0.0001 in all groups
of samples; ¥: comparison of mean value of CPD parameter evaluated for all 5 XN showed a significant difference on ANOVA with p<0.0001 in all groups of samples.
Highlighted in grey: Bias% is lower than the BALG%. BALG: alignment bias based on intra-individual biological variation; BAPS: analytical performance specification for Bias;
MOWX: monocyte complexity and width of dispersion of the events measured; MO-WY: monocyte fluorescence intensity and the width of dispersion; MO-WZ: monocyte cell
size and the width of dispersion; MO-X: monocyte cell complexity; MO-Y: monocyte fluorescence intensity; MO-Z: monocyte cell size; OMV: overall median.
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Table V Stability of CPD parameters in normal blood samples. Median Hodges-Lehmann location shift (DX); Bias% (B%) between baseline (T0)
and the time point (2 h up to 48 h) at 4 °C and Room Temperature (RT) comparison to BAPS% and Reference Change Value % (RCV%).
Parameters T [°C] T0 median value (95%CI)
DX (T-T0) absolute value 
Hodges-Lehmann location shift DX not 
significant
until [h]
B% (95%CI) 
at time of stability;
stable until [h]
B% (95%CI) at 
time is equal or lower
than RCV%; no 
clinical impact until [h]2h 4h 6h 8h 24h 36h 48h
NE-SSC 
(ch)
RT
147.8
(144.4 to 152.2)
-0.53 -1.19 -1.63 -2.2 -7.37 -10.7 -14.8 8h -0.4 (-0.6 to-0.1); 2h
-1.5 (-1.8 to -1.1); 
8h
4°C -1.85 -0.65 -2.1 -1.15 -3.95 -4.5 -6.6 36h not stable p<0.0001 -0.5 (-0.9 to -0.0); 8h
NE-SFL 
(ch)
RT
46.9
(46.2 to 50.2)
0.3 0.15 -0.8 -0.6 -3.1 -3.75 -3.7 8h 0.3 (-1.1 to 1.7); 4h
-7.2 (-9.0 to -5.4); 
24h
4°C -0.55 -0.3 -1.3 0.10 1.5 1.45 1.55 no difference
0.5 (-0.7 to 1.6); 
8h
no clinical impact 
over 48h
NE-FSC 
(ch)
RT
84.7 
(83.4 to 87.5)
1.7 0.2 0.2 -0.65 -12.3 -17.45 -2.1 8h -0.7 (-2.2 to 0.7); 8h
-0.7 (-2.2 to 0.7); 
24h
4°C 4.4 4.6 4.4 6.2 3.8 3.2 1.5 not stablep<0.0001 not stable p<0.0001
no clinical impact 
over 48h
NE-WX 
(ch)
RT
312.5
(291 to 328)
6.8 5.4 8.4 13.6 97.4 129.9 121.3 8h no stable p<0.0001 4.3 (2.3 to 6.3) 8h
4°C 23.0 28.0 28.0 31.0 44.0 55.5 77.5 not stablep<0.0001 not stable p<0.0001
8.8 (6.22 to 11.46); 
8h
NE-WY 
(ch)
RT
591.5
(578 to 615)
0.20 -3.20 -0.35 9.15 252.1 356.6 251.95 8h -0.05 (-1.6 to 1.5);6h
1.5 (-0.6 to 3.7); 
8h
4°C 9.5 4.0 17.5 3.0 34.0 31.0 71.0 8h not stable p<0.0001 5.5 (2.1 to 8.9); 24h
NE-WZ 
(ch)
RT
649.5
(632 to 749)
-9.0 -7.0 -3.0 19.0 524.5 756.5 425.5 8h 2.5 (-2.3 to 7.2); 8h
2.5 (-2.3 to 7.2) 
8h
4°C -21.0 15.0 13.0 39.0 52.0 76.5 140.0 24h 0.6 (-5.1 to 6.4);6h
9.0 (5.2 to 12.7); 
24h
LY-X 
(ch)
RT
77.7
(76.0 to 78.2)
0.41 0.55 0.64 1.07 1.49 2.7 3.17 24h 0.7 (0.0 to 1.4); 4h
no clinical impact 
over 48h
4°C 1.4 2.0 1.75 2.5 2.3 2.8 2.75 6h not stable p<0.0001 no clinical impact over 48h
LY-Y 
(ch)
RT
71.6
(68.5 to 73.1)
-0.02 -0.09 -0.82 -1.0 -5.04 -4.83 -7.28 8h -0.1 (-1.7 to 1.5); 4h
-7.3 (-8.9 to -5.7); 
24h
4°C 0.0 0.2 -0.55 0.4 -0.3 -0.5 -2.5 no difference
-0.3 (-1.3 to 0.8);
24h
no clinical impact 
over 48h
LY-Z 
(ch)
RT
55.1
(54.6 to 62.7)
-0.1 -0.4 -1.0 -0.9 -0.7 -1.1 0.1 no difference
0.05 (-0.6 to 0.7); 
2h
no clinical impact 
over 48h
4°C 0.7 2.1 1.9 3.3 3.8 3.4 3.0 6h not stable p<0.0001 no clinical impact over 48h
LY-WX 
(ch)
RT
486.0
(460.0 to 502.0)
16.5 6.5 10.5 12.0 32.5 19.0 46.0 36h 2.4 (-1.5 to 6.2); 8h
no clinical impact 
over 48h
4°C -3.0 4.0 -4.0 -17.0 71.0 97.5 112.5 8h -1.0 (-5.4 to 3.4); 6h
3.4 (-7.4 to 0.5); 
8h
LY-WY 
(ch)
RT
854.5
(808 to 898)
9.8 2.1 12.35 31.75 144.9 209.1 211.15 8h 0.2 (-4.2 to 4.6); 2h
3.8 (0.5 to 7.1);
8h
4°C -8.0 -9.5 0.0 5.0 56.0 81.0 195.5 24h 1.2 (-3.4 to 5.7); 8h
1.2 (-3.4 to 5.8); 
8h
LY-WZ 
(ch)
RT
543
(527 to 578)
-13.4 -27.85 -9.6 5.5 132.1 196.0 307.5 8h 0.96 (1.7 to 3.6); 8h
-2.6 (-6.1 to 0.9); 
24h
4°C -24.0 -23.0 -15.0 3.0 118.5 118.0 277.0 not stablep<0.0001 not stable p<0.0001 not stable p<0.0001
MO-X 
(ch)
RT
115.2
(114.8 to 117.3)
0.22 0.0 -0.87 -0.35 -3.43 -2.97 -2.41 8h -0.1 (-0.6 to -0.06);4h
no clinical impact 
over 48h
4°C 1.7 1.9 1.9 2.8 5.8 6.5 7.9 not stablep<0.0001 not stable p<0.0001
2.5 (2.0 to 2.9); 
8h
MO-Y 
(ch)
RT
109.3
(106.2 to 111.3)
1.36 -0.13 -2.4 -1.7 -16.3 -21.4 -28.3 8h -0.1 (-1.7 to 1.4); 4h
-1.6 (-3.4 to 0.3); 
8h
4°C -3.3 -1.6 -5.4 -2.55 -0.35 -0.65 -4.45 4h not stable p<0.0001 no clinical impact over 48h
MO-Z 
(ch)
RT
59.3
(58.6 to 65.9)
-0.1 -0.7 -1.6 -1.3 -3.25 -7.95 -4.55 24h 0.3 (-1.1 to 1.8); 2h
-3.0 (-5.3 to -0.7); 
8h
4°C -1.4 -0.3 -2.6 0.85 -1.2 -3.2 -7.1 24h not stable p<0.0001 4.1 (-1.5 to 9.7); 24h
MO-WX 
(ch)
RT
246.5
(237 to 260)
-0.4 -4.75 11.0 4.5 85.3 106.8 104.3 8h 1.72 (-2.3 to 5.7); 8h
28.4 (19.9 to 36.9);
24h
4°C 6.0 6.0 8.0 28.0 42.0 31.0 62.5 6h -0.2 (-4.5 to 4.0); 6h
no clinical 
impact over 48h
MO-WY 
(ch)
RT
706.5
(650 to 737)
8.50 -21.0 30.0 32.0 203.0 314.0 325.0 8h 0.6 (-4.6 to 5.8);2h
24.9 (11.6 to 38.2);
24h
4°C -14.5 -37.0 -5.0 -4.0 1.50 11.5 84.0 36h 0.1 (-8.0 to 8.2); 24h
0.1 (-8.2 to 8.2); 
24h
MO-WZ 
(ch)
RT
650.5
(605 to 711)
-14.3 -13.2 9.45 38.0 344.5 636.3 525.3 8h 5.4 (-2.6 to 13.4); 8h
5.4 (-2.6 to 13.4); 
8h
4°C 28.0 42.0 98.0 101.0 206.0 234.0 334.0 4h 3.8 (-2.3 to 9.8); 6h 
14.3 (11.2 to 17.5); 
8h
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Figure 1 Neutrophils cell population data before and after application of instrumental alignment factor of November (Moving
Average November 2015) on each XN module (i.e. XN-A, B, C, D, E). The box plot shows the median value as line. The 1st and
3rd as a box and the minimum and maximum as whiskers with the end cap for each parameter and for each XN module. 
a) Median value NE-SSC before application of instrumental alignment factor; b) median value NE-SFL before application of instrumental alignment
factor; c) median value NE-FCS before application of instrumental alignment factor; d) median value NE-SSC after application of instrumental
alignment factor; e) median value NE-SFL after application of instrumental alignment factor; f) median value NE-FCS after application of instru-
mental alignment factor.
Figure 2 Lymphocytes cell population data before and after application of instrumental alignment factor of November (Moving
Average November 2015) on each XN module (i.e. XN-A, B, C, D, E). The box plot shows the median value as line. The 1st and
3rd as a box and the minimum and maximum as whiskers with the end cap for each parameter and for each XN module.
a) Median value LY-X before application of instrumental alignment factor; b) median value LY-Y before application of instrumental alignment factor;
c) median value LY-Z before application of instrumental alignment factor; d) median value LY-X after application of instrumental alignment factor;
e) median value LY-Y after application of instrumental alignment factor; f) median value LY-Z after application of instrumental alignment factor.
Discussion
The aim of the study was to assess the current
degree of CPD harmonization, using five separate
Sysmex XN-modules allocated to the same clinical
laboratory. Regarding the imprecision of the separate
modules, only NE-SFC and LY-Y fulfilled the estab-
lished specifications for desirable imprecision (14).
Other CPD parameters only met the minimum
acceptable level of imprecision, whilst those reflecting
cellular dispersion (i.e., NE, LY and MO-WX, WY and
WZ) displayed unacceptable imprecision. This impor-
tant finding should hence persuade the manufacturer
to plan additional efforts for improving the current
analytical performance.
The study design for verification of instrumental
alignment was critical. Our study included five XN-
modules, but specific control material with target val-
ues is not available. For this reason, we decided to
use the OMV obtained for each parameter as the ref-
erence value. Our results confirm that comparing the
Bias% of each XN-Module to BAPS% may lead to
incorrect assumptions, thus failing to detect a lack of
instrumentation alignment. Conversely, the use of
BAGL% seems much more appropriate for identifying
poor instrumental alignment, as predictable. There -
fore, data generated after the application of IAF cor-
rection attests that this harmonization approach may
more effectively improve the alignment of CPD pa -
ram eters among different XN modules.
According to our data, the performance of CPD
parameters seems stable over time and, even more
importantly, we could demonstrate that the use of
data generated from normal routine samples (i.e., the
MA population) may be reliably used as an inexpen-
sive approach to improve harmonization of CPD
parameters among separate XN-modules allocated in
the same laboratory. The approach of calculating IAF
is not new to the field of laboratory medicine, since it
is successfully used for improving the harmonization
of coagulation testing among separate analyzers
using the identical reagents (i.e., adopting the so-
called instrument specific international sensitivity
index; ISI) (23). Notably, once the XN-Check is certi-
fied for monitoring the analytical performance of CPD
parameters, this control material may then be used
for daily internal quality control assessment, for even-
tually highlighting the need for recalibration and thus
ultimately improving inter-laboratory comparability. 
Regarding the stability of whole blood samples
at different temperatures, the data obtained in this
study are quite comparable, and all CPD parameters
seem more stable when maintained at room temper-
ature for up to 2–4 hours. Interestingly, samples were
found to be more stable at room temperature than at
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Figure 3 Monocytes cell population data before and after application of instrumental alignment factor of November (Moving
Average November 2015) on each XN module (i.e. XN-A, B, C, D, E). The box plot shown the median value as line. The 1st and
3rd as a box and the minimum and maximum as whiskers with the end cap for each parameter and for each XN module.
a) Median value MO-X before application of instrumental alignment factor; b) median value MO-Y before application of instrumental alignment
factor; c) median value MO-Z before application of instrumental alignment factor; d) median value MO-X after application of instrumental align-
ment factor; e) median value MO-Y after application of instrumental alignment factor; f) median value MO-Z after application of instrumental
alignment factor.
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